<DOC>
	<DOCNO>NCT02266355</DOCNO>
	<brief_summary>Pilot study evaluate activity omalizumab prevention recurrent oxaliplatin hypersensitivity reaction ( HSR ) oxaliplatin-sensitive patient . The study also evaluate safety omalizumab ( Xolair ) administer setting .</brief_summary>
	<brief_title>Role Omalizumab Reducing Incidence Oxaliplatin-induced Hypersensitivity Reaction</brief_title>
	<detailed_description>This open label single arm pilot study study effect omalizumab treatment oxaliplatin hypersensitivity reaction ( HSR ) patient stage IV GI cancer .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Clinically evident HSR oxaliplatin , symptom flush , urticaria , pruritus , rash , and/or dyspnea without bronchospasm emerge shortly oxaliplatin infusion Responding ( complete partial ) stable disease accord RECIST criterion undergo treatment oxaliplatin contain regimen need resume oxaliplatin base regimen set welldocumented recent oxaliplatin hypersensitivity reaction Histologically confirm stage IV GI cancer ( AJCC 7th edition ) currently sensitive oxaliplatin contain chemotherapy regimen Age 18 year old ECOG performance status 02 Adequate bone marrow , liver , kidney function . ( WBC &gt; 1500 cells/uL , platelet &gt; 50,000/uL , ALT/AST &lt; 5xULN ( unless due liver metastasis ) , Creatinine &lt; 2.0 mg/ld ) Willing give write informed consent , adhere visit schedule meet study requirement Prior history severe reaction oxaliplatin characterize presence hemodynamic instability , significant respiratory symptom potential airway compromise History hypersensitivity reaction Xolair ingredient Xolair Concurrent therapy investigational agent Use investigational agent last 15 day toxicity prior therapy resolved Psychological , familial , sociological condition potentially hamper compliance study protocol followup schedule Women childbearing potential use contraception method ( ) , well woman breastfeed Patients severe medical condition view investigator prohibits participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Oxaliplatin</keyword>
	<keyword>Omalizumab</keyword>
</DOC>